Dr Reddy's launches bivalirudin injection in US

Bivalirudin, a direct thrombin inhibitor, is used to prevent blood clots in people

premium

BS B2B Bureau Hyderabad

Last Updated : Jun 06 2017 | 12:52 PM IST

Dr Reddy’s Laboratories Ltd has launched bivalirudin for injection (250 mg per vial), which has been approved by the US Food and Drug Administration (FDA). The product is a generic version of The Medicines Company’s Angiomax. Dr Reddy’s bivalirudin injection will be available in packages of 10 single-dose vials.

Bivalirudin, a direct thrombin inhibitor, is used to prevent blood clots in people with severe chest pain or other conditions who are undergoing a procedure called angioplasty (to open blocked arteries).

The Angiomax brand and generic had US sales of approximately $ 198 million MAT for the most recent twelve months ending in March 2017, according to IMS Health.